Drugs & Treatments | malecare.org

Abiraterone And Enzalutamide Effect Cognitive Impairment and Depression in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Speaking with men who have taken abiraterone (Zytiga, ABI) and enzalutamide (Xtandi, ENZA), at Malecare we sometimes hear reports of both cognitive and mood changes brought on by these two drugs. Evaluating these two problematic side effects researchers have confirmed our experience, both of these drugs can cause these symptoms and that more men reported [...]

By Malecare|2016-06-14T09:24:42-04:00June 14th, 2016|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, enzalutamide, Uncategorized, Understanding Advanced Prostate Cancer, Xtandi, Zytiga|0 Comments

Understanding the Complexity of Prostate Cancer Drug Names – Cutting Through The Confusion

As drugs are developed they are given many different names, but the drug (or treatment) is the same despite its name. For us laymen, multiple names for the same drug is confusing. So, why are there so many different names for the same thing? Drugs usually have three different names; A chemical name that relates [...]

By Malecare|2017-10-19T10:46:20-04:00May 23rd, 2016|Advanced Prostate Cancer, Drugs & Treatments, Uncategorized|0 Comments

An Independent Prognostic Tool For Men With Metastatic Castrate Resistant Prostate Cancer Taking The Newer Drugs

We have a number of newer hormone pathway drugs now available to treat men with metastatic castrate resistant prostate cancer (mCRPC). Researchers have shown that prostate specific antigen (PSA) response can be used as a pharmaco-dynamic end-point that may help identify men with early resistance to these new drugs. They found that there is clinical [...]

By Malecare|2020-02-04T11:38:56-05:00May 12th, 2016|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Biomarkers and Prognostic Tools, Drugs & Treatments, enzalutamide, prognostic tools, PSA, Research, Uncategorized, Understanding Advanced Prostate Cancer, Xtandi, Zytiga|1 Comment

Early Hormone Therapy In Men With A Rising PSA Live Longer Then Men Who Delay Therapy – A Phase 3 Trial

The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is [...]

By Malecare|2017-10-19T10:46:21-04:00May 11th, 2016|ADT, Advanced Prostate Cancer, Australia, Canada, Clinical Trials, Drugs & Treatments, survival, Survival, Uncategorized, Understanding Advanced Prostate Cancer, United Kingdom - England, Northern Ireland, Scotland & Wales|0 Comments

Short Term Androgen Therapy Might Be Better For More Aggressive Gleason Grade Prostate Cancer

In a recently published commentary about the optimal type of multi-modal hormone therapy for Gleason grade 4 and 5 prostate cancer the author addressed the discordance between results of several randomized trials evaluating survival benefit of continuous androgen deprivation therapy in men with high-risk disease. The study found that after combining data from multiple trials, [...]

By Malecare|2023-07-08T15:57:46-04:00May 10th, 2016|Advanced Prostate Cancer, Clinical Trials & Research, Drugs & Treatments, General Information, Gleason Score, Hormone Therapy, Uncategorized, Understanding Advanced Prostate Cancer|0 Comments